Prodotto aggiunto correttamente al carrello.

discount label
H-APGSTAPPA-OH
Visualizzare in 3D

Biosynth logo

H-APGSTAPPA-OH

Rif. 3D-PP46410

1mg
217,00 €
10mg
253,00 €
100mg
455,00 €
Consegna stimata in Stati Uniti, il Venerdì 27 Dicembre 2024

Informazioni sul prodotto

Nome:
H-APGSTAPPA-OH
Sinonimi:
  • NH2-Ala-Pro-Gly-Ser-Thr-Ala-Pro-Pro-Ala-OH
Descrizione:

Peptide H-APGSTAPPA-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-APGSTAPPA-OH include the following: Combined MUC1 Vaccination and Anti-PD1 Antibody Treatment Boosts Anti-Tumor Immune Response in Mouse Models of Colon Cancer Y Ma , J Shen, M Wang, D Wang, D Li, X Wang - Available at SSRN - papers.ssrn.comhttps://papers.ssrn.com/sol3/papers.cfm?abstract_id=3994512 Genetically Modified T Cell Therapy Optimisation of the Chimeric T Cell Receptor for Cancer Therapy W Mansoor, A O'Neil, D Gillham - Journal of , 2004 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2004/11000/genetically_modified_t_cell_therapy_optimisation.18.aspx MUC1 vaccines, comprised of glycosylated or non-glycosylated peptides or tumor-derived MUC1, can circumvent immunoediting to control tumor growth in MUC1 V Lakshminarayanan, NT Supekar , J Wei, DB McCurry - PloS one, 2016 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0145920 Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. V Apostolopoulos , V Karanikas, JS Haurum - (Baltimore, Md.: 1950 , 1997 - journals.aai.orghttps://journals.aai.org/jimmunol/article-abstract/159/11/5211/30949 MUC1 peptide epitopes associated with five different H-2 class I molecules V Apostolopoulos , JS Haurum - European journal of , 1997 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830271017 Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design V Apostolopoulos , IF McKenzie, IA Wilson - Front Biosci, 2001 - article.imrpress.comhttps://article.imrpress.com/bri/Landmark/articles/pdf/LandmarkA683.pdf Anti-MUC1 antibodies react directly with MUC1 peptides presented by class I H2 and HLA molecules V Apostolopoulos , G Chelvanayagam - The Journal of , 1998 - journals.aai.orghttps://journals.aai.org/jimmunol/article/161/2/767/31120 Noncanonical peptides in complex with MHC class I V Apostolopoulos , E Lazoura - Expert Review of Vaccines, 2004 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1586/14760584.3.2.151 Immunotherapeutic Strategies in Breast Cancer: Preclinical and Clinical Trials SJ Gendler, MAYO CLINIC SCOTTSDALE AZ - 2002 - apps.dtic.milhttps://apps.dtic.mil/sti/citations/tr/ADA582548 Anti-mucin monoclonal antibodies PX Xing, V Apostolopoulos , G Pietersz, IF McKenzie - Front Biosci, 2001 - researchgate.nethttps://www.researchgate.net/profile/Vasso-Apostolopoulos/publication/11769574_Anti-mucin_monoclonal_antibodies/links/53e4b8e20cf25d674e94e319/Anti-mucin-monoclonal-antibodies.pdf Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model P Mukherjee , TL Tinder, GD Basu - Breast , 2004 - content.iospress.comhttps://content.iospress.com/articles/breast-disease/bd000158 MUC1-specific immune therapy generates a strong anti-tumor response in a MUC1-tolerant colon cancer model P Mukherjee , LB Pathangey, JB Bradley, TL Tinder - Vaccine, 2007 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X06012035 Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer P Mukherjee , CS Madsen, AR Ginardi - Journal of , 2003 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2003/01000/Mucin_1_Specific_Immunotherapy_in_a_Mouse_Model_of.6.aspx MUC1-specific Cytotoxic T Lymphocytes Eradicate Tumors When Adoptively Transferred in Vivo P Mukherjee , AR Ginardi, TL Tinder, CJ Sterner - Clinical cancer , 2001 - AACRhttps://aacrjournals.org/clincancerres/article-abstract/7/3/848s/200197 MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment P Mukherjee , AR Ginardi, CS Madsen, TL Tinder - Glycoconjugate , 2001 - Springerhttps://link.springer.com/article/10.1023/A:1022260711583 Peptide-based vaccine against breast cancer: recent advances and prospects ML Nordin , AK Azemi , AH Nordin, W Nabgan , PY Ng - Pharmaceuticals, 2023 - mdpi.comhttps://www.mdpi.com/1424-8247/16/7/923 Synthesis of cholera toxin B subunit glycoconjugates using site-specific orthogonal oxime and sortase ligation reactions JP Dolan , DC Machin , S Dedola, RA Field - Frontiers in , 2022 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fchem.2022.958272/full Indomethacin enhances anti-tumor efficacy of a MUC1 peptide vaccine against breast cancer in MUC1 transgenic mice JM Curry, DM Besmer, TK Erick , N Steuerwald - PLoS , 2019 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0224309 DC1-Based Protocols for Adoptive Immunotherapy for PTLD Boost Type-1 Anti-EBV CD8+ T Cell Responses in Solid Organ Tranplant Patients I Popescu , C Macedo, A Zeevi, R Shapiro - Journal of , 2004 - journals.lww.comhttps://journals.lww.com/immunotherapy-journal/fulltext/2004/11000/DC1_Based_Protocols_for_Adoptive_Immunotherapy_for.22.aspx Expression and in vitro glycosylation of recombinant edible bird nest (EBN) mucin G Cheng, Y Lyu, R Ran, L Liu - Food Materials , 2024 - maxapress.comhttps://www.maxapress.com/article/doi/10.48130/fmr-0023-0037?viewType=HTML Characterization of the MUC1. Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas ET Akporiaye, D Bradley-Dunlop, SJ Gendler - Vaccine, 2007 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0264410X07007438 Non-canonical anchor motif peptides bound to MHC class I induce cellular responses E Lazoura, J Lodding, W Farrugia, S Day - Molecular , 2009 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0161589008007578

Avviso:
I nostri prodotti sono destinati esclusivamente ad uso di laboratorio. Per qualsiasi altro utilizzo, vi preghiamo di contattarci.
Marchio:
Biosynth
Conservazione lunga:
Note:

Proprietà chimiche

MDL:
Punto di fusione:
Punto di ebollizione:
Punto di infiammabilità:
Densità:
Concentrazione:
EINECS:
Merck:
Codice SA:

Informazioni sui pericoli

Numero ONU:
EQ:
Classe:
Indicazioni di pericolo:
Consigli di prudenza:
Vietato trasportare in aereo:
Informazioni sui pericoli:
Gruppo di imballaggio:
LQ:

Richiesta tecnica su: 3D-PP46410 H-APGSTAPPA-OH

Si prega di utilizzare piuttosto il carrello per richiedere un preventivo o un ordine

Se si desidera richiedere un preventivo o effettuare un ordine, si prega invece di aggiungere i prodotti desiderati al carrello e poi richiedere un preventivo o un ordine dal carrello. È più veloce, più economico, e potrà beneficiare degli sconti disponibili e di altri vantaggi.

* Campi obbligatori
Benvenuto su CymitQuimica!Utilizziamo i cookie per migliorare la tua visita. Non includiamo pubblicità.

Consulta la nostra Politica sui Cookie per maggiori dettagli o regola le tue preferenze in "Configura".